

Public pipeline

Phase 1	Phase 2	Phase 3	Registration	
TV-46139 (abuse deterrent) <i>Pain</i>	TV-45070 Topical <i>Neuropathic pain</i>	Fremanezumab (anti CGRP) <i>Chronic migraine (Global)</i>	Deutetrabenazine, SD-809 <i>Huntington Disease</i>	<div style="background-color: #1a3d54; color: white; padding: 20px; text-align: center;"> <p>25 products in phase 1 through submission</p> </div> <ul style="list-style-type: none"> Migraine & Pain 9 Neurology & neuropsychiatry 9 Respiratory 5 Biosimilars 2
TEV-90105 (abuse deterrent) <i>Pain</i>	Fasinumab ** <i>Chronic Lower Back Pain</i>	Fremanezumab (anti CGRP) <i>Episodic migraine (Global)</i>	Deutetrabenazine, SD-809 <i>Tardive dyskinesia</i>	
Deutetrabenazine, SD-809 <i>Tourette syndrome</i>	Laquinimod <i>Multiple sclerosis (primary progressive)</i>	Fremanezumab (anti CGRP) <i>Cluster Headache (Global)</i>	QVAR® (beclomethasone dipropionate BAI) <i>Asthma (U.S.)</i>	
Deulevodopa, SD-1077 <i>Parkinson's Disease</i>	Laquinimod <i>Huntington disease</i>	TV-46763 (abuse deterrent) <i>Pain</i>	Reslizumab* IV <i>Asthma (Global)</i>	
TV-46000 <i>Schizophrenia</i>	Pridopidine <i>Huntington disease</i>	Fasinumab ** <i>Osteoarthritis pain</i>	Fluticasone Propionate MDPI <i>Asthma (Growth markets)</i>	
		Laquinimod <i>Multiple sclerosis (relapsing remitting)</i>	Fluticasone Salmeterol MDPI <i>Asthma (Growth markets)</i>	
		Reslizumab* SC <i>Asthma (Global)</i>		
		CT-P10 *** <i>Biosimilar (Rituxan® U.S.)</i>		
		CT-P6 *** <i>Biosimilar (Herceptin® U.S.)</i>		

1 Note: Pipeline is current as of Feb 1st, 2017. Phase 1 includes also projects designated for IND filing.

* Approved in the U.S under the trade name: CINQAIR® **In partnership with Regeneron *** In partnership with Celltrion